A CRISPR enzyme that reads a cancer's mutant RNA, then shreds the cell from inside
Cas9 cuts DNA at one spot. Cas12a2 does something stranger: once it spots a tumor-only RNA transcript, it goes berserk and chops up everything in the cell. The trigger is a single-nucleotide difference between a sick cell and a healthy one.
The trick targets p53, the mutated tumor-suppressor behind nearly half of all cancers and long called 'undruggable' because the broken protein has no pocket for a drug to grab. Instead of fixing the protein, the system uses the mutant transcript itself as a self-destruct trigger.
A biologist in the thread cut the hype: every previous version of this idea used Cas9, which just nicks DNA. This one's whole point is collateral damage. And the same crowd flagged the catch nobody markets: getting the enzyme into every cancer cell in a body.
A CRISPR system that kills a cell for the crime of having the wrong RNA
The Innovative Genomics Institute write-up (860 points in the thread) describes work from Jennifer Doudna's lab on a CRISPR enzyme that does the opposite of precision editing. It is engineered to be sloppy on purpose.
The mechanism: a single-nucleotide tripwire that detonates the genome
Most CRISPR therapies use Cas9 to make one clean cut at one DNA address. The new approach, published in Nature as Targeting Cancer-Specific Mutations with RNA-Triggered Chromatin Shredding, uses a different enzyme, Cas12a2, and a different logic.
The guide RNA is designed to recognize a transcript that only a cancer cell produces: the mutant p53 messenger RNA. When Cas12a2 binds that target, it doesn't stop at the target. It switches into a non-specific shredding mode and begins cleaving collateral RNA and DNA throughout the cell, tearing up the chromatin until the cell dies. A healthy cell, whose p53 transcript differs by as little as one nucleotide, never trips the wire and is left alone.
That is the conceptual move: not repair the broken protein, but use the broken protein's own RNA as a death trigger. Lead author Jingkun Zeng framed the precision claim directly: "It's the first time we managed to target p53 with such precision," noting the system can tell apart disease and healthy cells differing by a single nucleotide.
Why "undruggable" is the headline word
p53 is mutated in roughly half of all cancers, and in 70 to 90% of some of the deadliest, including ovarian, pancreatic, and non-small-cell lung. It has stayed out of reach because conventional drugs work by physically docking into a pocket on a protein, and a mutated, misfolded p53 offers no good pocket to grab. "Undruggable" is the shorthand for exactly that: a driver mutation that small molecules can't latch onto. Reading the mutant's RNA sidesteps the protein entirely. The study reports the approach working in mouse models of lung and liver tumors, with collaborators at UCSF and the Gladstone Institutes.
The biologist who deflated the novelty, then named the real innovation
The sharpest read came from someone who knew the prior literature cold.
"The idea of using CRISPR/Cas to detect tumor-specific mutations… and then kill the cell is not a new one… However, previous studies used Cas9, which just damages the DNA at the target site; this uses Cas12a2, which is far more destructive because it shreds the chromatin in the cell once activated" — a commenter citing three prior papers on the same concept
The same comment predicted the failure mode any oncologist expects: resistance. Tumors could learn to reject the lipid nanoparticles that carry the CRISPR payload, or degrade the mRNA before it's ever translated.
That points at the asterisk the press release soft-pedals. A Perl 6 core developer reading the IGI line about delivery being "a critical challenge" took it as a tell:
"makes me think this is in vitro so far. So, years to decades away from being available for actual treatment in humans. Still good news." — a longtime open-source developer
Delivery is the wall the whole field keeps hitting. To cure a cancer this way you have to reach essentially every malignant cell and scan its nucleus, as one engineer spelled out:
"In order to kill all cancer cells in the body, it probably needs to be delivered to every single cell… Viruses usually don't infect every single cell, just a small percentage." — a developer working through the delivery math
The contrarian: CRISPR is the press cycle, not the cure
One voice attacked the whole frame, arguing the genre of "CRISPR breakthrough" stories oversells a technology that has barely shipped:
"There is 1 FDA approved CRISPR therapy as compared to 7 for AAV and 7 for Lentivirus… viral vector delivery is the real future. It just didn't get the same news cycle." — a commenter tallying approved gene therapies
And the race is already crowded: another reader pointed out a second group published the same RNA-triggered approach in Nature. For anyone who wants the primary sources past the press release, the bioRxiv preprint and the Nature paper were both linked in the thread.
The honest summary sits between the two camps. The chemistry is genuinely new: turning a transcript into a self-destruct command lets you go after drivers that have no druggable pocket. But "works in a mouse tumor and a dish" is the start of the hardest part, not the end. Resistance and delivery have killed cleaner ideas than this one.
Get breakdowns like this every day
The top Hacker News stories, unpacked — by email, Telegram, or RSS.
Postgres 19 can finally answer: what did this row look like last Tuesday?
For years, time-travel queries in Postgres meant hand-rolled date ranges and GIST index gymnastics. PG19 brings the SQL:2011 temporal features native — overlap-proof primary keys, time-sliced updates, and period foreign keys. The engineer who built it showed up in the thread.